receiving invasive (any mode where a patient has been intubated endotracheally, or via tracheostomy) or non-invasive (for instance, but not restricted to cpap, psv, pcv, simv) mechanical ventilation before or upon randomization. pregnancy or breast feeding. any medical condition which would impose an unacceptable safety hazard by participation to the study. patients with a documented grade 3 allergic reaction after the administration of fresh frozen plasma (i.e. systemic reaction with cardiovascular and/or respiratory involvement) patients that have treatment restriction that excludes mechanical ventilation and/or endotracheal intubation rituximab or another anti-cd20 monoclonal antibody (f.ex. obinutuzumab) has been administered during the year prior of the date of admission.

receiving invasive (any mode where a patient has been intubated endotracheally, or via tracheostomy) or non-invasive (for instance, but not restricted to cpap, psv, pcv, simv) mechanical ventilation before or upon randomization. pregnancy or breast feeding. any medical condition which would impose an unacceptable safety hazard by participation to the study. patients with a documented grade 3 allergic reaction after the administration of fresh frozen plasma (i.e. systemic reaction with cardiovascular and/or respiratory involvement) patients that have treatment restriction that excludes mechanical ventilation and/or endotracheal intubation rituximab or another anti-cd20 monoclonal antibody (f.ex. obinutuzumab) has been administered during the year prior of the date of admission.

1. receiving invasive (any mode where a patient has been intubated endotracheally, or via tracheostomy) or non-invasive (for instance, but not restricted to cpap, psv, pcv, simv) mechanical ventilation before or upon randomization. 2. pregnancy or breast feeding. 3. any medical condition which would impose an unacceptable safety hazard by participation to the study. 4. patients with a documented grade 3 allergic reaction after the administration of fresh frozen plasma (i.e. systemic reaction with cardiovascular and/or respiratory involvement) 5. patients that have treatment restriction that excludes mechanical ventilation and/or endotracheal intubation 6. rituximab or another anti-cd20 monoclonal antibody (f.ex. obinutuzumab) has been administered during the year prior of the date of admission.

1. receiving invasive (any mode where a patient has been intubated endotracheally, or via tracheostomy) or non-invasive (for instance, but not restricted to cpap, psv, pcv, simv) mechanical ventilation before or upon randomization. 2. pregnancy or breast feeding. 3. any medical condition which would impose an unacceptable safety hazard by participation to the study. 4. patients with a documented grade 3 allergic reaction after the administration of fresh frozen plasma (i.e. systemic reaction with cardiovascular and/or respiratory involvement) 5. patients that have treatment restriction that excludes mechanical ventilation and/or endotracheal intubation 6. rituximab or another anti-cd20 monoclonal antibody (f.ex. obinutuzumab) has been administered during the year prior of the date of admission.

1. receiving invasive (any mode where a patient has been intubated endotracheally, or via tracheostomy) or non-invasive (for instance, but not restricted to cpap, psv, pcv, simv) mechanical ventilation before or upon randomization. 2. pregnancy or breast feeding. 3. any medical condition which would impose an unacceptable safety hazard by participation to the study. 4. patients with a documented grade 3 allergic reaction after the administration of fresh frozen plasma (i.e. systemic reaction with cardiovascular and/or respiratory involvement) 5. patients that have treatment restriction that excludes mechanical ventilation and/or endotracheal intubation

1. receiving invasive (any mode where a patient has been intubated endotracheally, or via tracheostomy) or non-invasive (for instance, but not restricted to cpap, psv, pcv, simv) mechanical ventilation before or upon randomization. 2. pregnancy or breast feeding. 3. any medical condition which would impose an unacceptable safety hazard by participation to the study. 4. patients with a documented grade 3 allergic reaction after the administration of fresh frozen plasma (i.e. systemic reaction with cardiovascular and/or respiratory involvement) 5. patients that have treatment restriction that excludes mechanical ventilation and/or endotracheal intubation